New hope for liver cancer: triple therapy trial launches

NCT ID NCT07219459

Recruiting now Disease control Sponsor: CatalYm GmbH Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 26 times

Summary

This study tests whether adding visugromab to standard treatments (nivolumab and lenvatinib) can help people with advanced liver cancer that has stopped responding to initial therapy. About 104 adults with unresectable or metastatic hepatocellular carcinoma and good liver function will participate. The goal is to see if the combination delays cancer growth or improves response rates.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UNRESECTABLE OR METASTATIC HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Asst Grande Ospedale Metropolitano Niguarda
RECRUITING

Milan, 20162, Italy

Contact Phone: •••-•••-•••• Email: •••••@•••••
Universitätsklinikum Frankfurt Johann Wolfgang Goethe- Universität
RECRUITING

Frankfurt, 60590, Germany

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

CHILD-PUGH A HEPATOCELLULAR CARCINOMA CHILD-PUGH A HEPATOCELLULAR CARCINOMA FAILURE OF FIRST-LINE TREATMENT THAT INCLUDED AN ANTI PD-(L)1 COMPOUND FAILURE OF FIRST-LINE TREATMENT THAT INCLUDED AN APPROVED ANTI PD-(L)1 COMPOUND UNRESECTABLE OR METASTATIC HEPATOCELLULAR CARCINOMA